{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:30:42Z","timestamp":1789126242399,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T00:00:00Z","timestamp":1402531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00380-014-0534-3","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T09:25:14Z","timestamp":1402478714000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide"],"prefix":"10.1007","volume":"30","author":[{"given":"Shintaro","family":"Haruki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"534_CR1","first-page":"1308","volume":"287","author":"BJ Maron","year":"2002","unstructured":"Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. J Am Med Assoc 287:1308\u20131320","journal-title":"J Am Med Assoc"},{"key":"534_CR2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199703133361107","volume":"336","author":"P Spirito","year":"1997","unstructured":"Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775\u2013785","journal-title":"N Engl J Med"},{"key":"534_CR3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/heart.87.2.169","volume":"87","author":"WJ McKenna","year":"2002","unstructured":"McKenna WJ, Behr ER (2002) Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 87:169\u2013176","journal-title":"Heart"},{"key":"534_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cardfail.2011.01.015","volume":"17","author":"H Kawarai","year":"2011","unstructured":"Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H (2011) Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17:459\u2013464","journal-title":"J Card Fail"},{"key":"534_CR5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00380-013-0332-3","volume":"28","author":"E Fujita","year":"2013","unstructured":"Fujita E, Nakanishi T, Nishizawa T, Hagiwara N, Matsuoka R (2013) Mutations in the cardiac troponin T gene show various prognoses in Japanese patients with hypertrophic cardiomyopathy. Heart Vessel 28:785\u2013794","journal-title":"Heart Vessel"},{"key":"534_CR6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00380-012-0300-3","volume":"28","author":"Y Hen","year":"2013","unstructured":"Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessel 28:742\u2013749","journal-title":"Heart Vessel"},{"key":"534_CR7","author":"S Okayama","year":"2013","unstructured":"Okayama S, Soeda T, Kawakami R, Takami Y, Somekawa S, Ueda T, Sugawara Y, Matsumoto T, Sung JH, Nishida T, Uemura S, Saito Y (2013) Evaluation of coronary artery disease and cardiac morphology and function in patients with hypertrophic cardiomyopathy, using cardiac computed tomography. Heart Vessels. doi: 10.1007\/s00380-013-0452-9","journal-title":"Heart Vessels"},{"key":"534_CR8","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","volume":"58","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation, American Heart Association Task Force on Practice G (2011) 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58:e212\u2013e260","journal-title":"J Am Coll Cardiol"},{"key":"534_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295\u2013303","journal-title":"N Engl J Med"},{"key":"534_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/01.CIR.29.1.84","volume":"29","author":"DC Harrison","year":"1964","unstructured":"Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr (1964) Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29:84\u201398","journal-title":"Circulation"},{"key":"534_CR11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0002-9149(81)90086-2","volume":"48","author":"DR Rosing","year":"1981","unstructured":"Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE (1981) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 48:545\u2013553","journal-title":"Am J Cardiol"},{"key":"534_CR12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ (2005) Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 45:1251\u20131258","journal-title":"J Am Coll Cardiol"},{"key":"534_CR13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.84.4.1831","volume":"84","author":"The Sicilian gambit","year":"1991","unstructured":"The Sicilian gambit (1991) A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task force of the working group on arrhythmias of the European Society of Cardiology. Circulation 84:1831\u20131851","journal-title":"Circulation"},{"key":"534_CR14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","volume":"42","author":"BJ Maron","year":"2003","unstructured":"Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology\/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687\u20131713","journal-title":"J Am Coll Cardiol"},{"key":"534_CR15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.92.7.1680","volume":"92","author":"ED Wigle","year":"1995","unstructured":"Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92:1680\u20131692","journal-title":"Circulation"},{"key":"534_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.CIR.97.1.41","volume":"97","author":"MV Sherrid","year":"1998","unstructured":"Sherrid MV, Pearle G, Gunsburg DZ (1998) Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97:41\u201347","journal-title":"Circulation"},{"key":"534_CR17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/hrt.44.5.488","volume":"44","author":"DS Thompson","year":"1980","unstructured":"Thompson DS, Naqvi N, Juul SM, Swanton RH, Coltart DJ, Jenkins BS, Webb-Peploe MM (1980) Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 44:488\u2013498","journal-title":"Br Heart J"},{"key":"534_CR18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.CIR.72.4.853","volume":"72","author":"RO Bonow","year":"1985","unstructured":"Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV (1985) Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72:853\u2013864","journal-title":"Circulation"},{"key":"534_CR19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.51.5.523","volume":"51","author":"DM Anderson","year":"1984","unstructured":"Anderson DM, Raff GL, Ports TA, Brundage BH, Parmley WW, Chatterjee K (1984) Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J 51:523\u2013529","journal-title":"Br Heart J"},{"key":"534_CR20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","volume":"62","author":"M Sherrid","year":"1988","unstructured":"Sherrid M, Delia E, Dwyer E (1988) Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 62:1085\u20131088","journal-title":"Am J Cardiol"},{"key":"534_CR21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0002-8703(93)90760-7","volume":"125","author":"BP Kimball","year":"1993","unstructured":"Kimball BP, Bui S, Wigle ED (1993) Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 125:1691\u20131697","journal-title":"Am Heart J"},{"key":"534_CR22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","volume":"307","author":"C Pollick","year":"1982","unstructured":"Pollick C (1982) Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 307:997\u2013999","journal-title":"N Engl J Med"},{"key":"534_CR23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2010.06.059","volume":"106","author":"K Kajimoto","year":"2010","unstructured":"Kajimoto K, Imai T, Minami Y, Kasanuki H (2010) Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol 106:1307\u20131312","journal-title":"Am J Cardiol"},{"key":"534_CR24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/01.CIR.96.5.1520","volume":"96","author":"M Hamada","year":"1997","unstructured":"Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, Ochi T, Hiwada K (1997) Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96:1520\u20131524","journal-title":"Circulation"},{"key":"534_CR25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0735-1097(00)00830-5","volume":"36","author":"MV Sherrid","year":"2000","unstructured":"Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G (2000) Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 36:1344\u20131354","journal-title":"J Am Coll Cardiol"},{"key":"534_CR26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000177052","volume":"87","author":"M Hongo","year":"1996","unstructured":"Hongo M, Nakatsuka T, Takenaka H, Tanaka M, Watanabe N, Yazaki Y, Sekiguchi M (1996) Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Cardiology 87:6\u201311","journal-title":"Cardiology"},{"key":"534_CR27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","volume":"321","author":"The Cardiac Arrhythmia Suppression Trial (CAST) investigators","year":"1989","unstructured":"The Cardiac Arrhythmia Suppression Trial (CAST) investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406\u2013412","journal-title":"N Engl J Med"},{"key":"534_CR28","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.1993.03510200057032","volume":"270","author":"AE Epstein","year":"1993","unstructured":"Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG (1993) Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). J Am Med Assoc 270:2451\u20132455","journal-title":"J Am Med Assoc"},{"key":"534_CR29","doi-asserted-by":"crossref","first-page":"101B","DOI":"10.1016\/0002-9149(84)90511-3","volume":"53","author":"GD Gentzkow","year":"1984","unstructured":"Gentzkow GD, Sullivan JY (1984) Extracardiac adverse effects of flecainide. Am J Cardiol 53:101B\u2013105B","journal-title":"Am J Cardiol"},{"key":"534_CR30","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232\u20132239","journal-title":"Circulation"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-014-0534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-014-0534-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-014-0534-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:09:16Z","timestamp":1559056156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-014-0534-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s00380-014-0534-3","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}